Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors


    Training On Selecting the Right Contract Lab using Risk Based Approach

    View: 710

    Website http://compliance2go.com/index.php | Want to Edit it Edit Freely

    Category Pharma

    Deadline: February 26, 2013 | Date: February 27, 2013

    Venue/Country: Houstan, U.S.A

    Updated: 2013-02-08 20:00:42 (GMT+9)

    Call For Papers - CFP

    Why should you Attend :

    Due to the economy, many large pharma companies are right-sizing and creating opportunities for smaller pharmaceutical companies. However, most of the small companies typically do not have resources and technical expertise to fully support projects when needed. Therefore, they usually turn to outsourcing to fill the gaps. Selecting a contract lab is critical as they will be an extension of your lab and could help or jeopardize your project. This session will bring up different quality systems to look for in a contract lab.

    Description of the Webinar :

    Outsourcing becomes crucial to pharmaceutical industry. With the volatility of the economy coupling with the stream of corporate mergers, companies are pressured to turn to outsourcing as an extension of their laboratory. Project management, technical capabilities, data collaborations, quality assurance are areas that might be affected. This session will discuss key factors to consider when selecting a CRO for your analytical projects, and how critical activities should be monitor to ensure quality and safety of pharmaceutical products in global development.

    Areas Covered in the Session:

    System based inspections

    Selecting a Contract Lab

    Perform a technical evaluation

    Audit CRO for analytical testing

    Establish SOP for operations

    How to communicate expectations

    How to monitor processes

    Who will benefit: (Titles)

    Pharmaceutical development and manufacturing

    Manufacturers of raw material and ingredients

    Analysts and lab managers

    QA managers and personnel

    Regulatory affairs

    QC personnel and managers

    Webinar Includes

    -Q/A Session with the Expert to ask your question

    -PDF print only copy of PowerPoint slides

    -60 Minutes Live Presentation

    -Certificate of Attendance

    About Speaker

    Kim Huynh-Ba: As the founder and technical director of Pharmalytik, Kim Huynh-Ba's expertise focusses in Analytical Development, Method Development/Validation/Transfer, Stability and Outsourcing Project management. She has over 20 years of experiences in various areas of pharmaceutical development working with Wyeth, DuPont Pharmaceuticals, Bristol-Myers Squibb, ICI Americas (currently Astra Zeneca). In 2002, she has started her consulting and training organization. Her current clients include various sizes of pharmaceutical companies including those are under Consent Decree.

    Kim Huynh-Ba is an active member of ACS, AAPS, PSDG, ASQ, POMA and serves in the Governing Board of Eastern Analytical Symposium (EAS). She is the founder and past-chair of the AAPS Stability Focus Group, and was on the Steering Committee of AAPS CMC Focus Group. She also is chairing EAS 2008 Short Course Program and AAPS APQ Distance Learning Office.

    Kim Huynh-Ba received the 2008 Leadership Award from APQ and the 2008 Recognition Award from AAPS Regulatory Sciences.

    Speaker : Kim Huynh-Ba

    Product ID : F62184

    Schedule Date :

    Wednesday, February 27, 2013

    duration : 01:00 to 02:00 PM EST

    https://compliance2go.com/index.php?option=com_training&speakerkey=51&productKey=211


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.